Severity of Omicron BA.5 variant and protective effect of vaccination: national cohort and matched analyses in Scotland

Authors: Robertson, Chris;

Kerr, Steven ;

Sheikh, Aziz

Source: The Lancet Regional Health Europe

Full text

: https://doi.org/10.1016/j.lanepe.2023.100638 10.1016/j.lanepe.2023.100638

Abstract

The BA.5 sub-lineage was first detected in South Africa in January 2022. It was designated a variant of concern by the UK Health and Security Agency on May 18, 2022, and became dominant in the UK by June 24, 2022. There are few longitudinal population-based studies on the risks of infection and serious COVID-19 outcomes of BA. A case control and cross-sectional study in Denmark found that BA.5 was associated with an increased risk of COVID-19 hospitalisation compared to BA.2. A test negative case–control study in England found no evidence of reduced vaccine effectiveness (VE) against hospitalisation for BA.5 compared to BA.2. In this study, we analysed severity of the BA.5 variant compared to BA.2, which was the most recent dominant Omicron sub-lineage in the UK prior to BA.5.

Rights

http://creativecommons.org/licenses/by-nc-nd/4.0/

Cite as

Robertson, C., Kerr, S. & Sheikh, A. 2023, 'Severity of Omicron BA.5 variant and protective effect of vaccination: national cohort and matched analyses in Scotland', The Lancet Regional Health Europe, 28, article no: 100638. https://doi.org/10.1016/j.lanepe.2023.100638 10.1016/j.lanepe.2023.100638

Downloadable citations

HTML BIB RIS

Identifiers

DOI: https://doi.org/10.1016/j.lanepe.2023.100638 10.1016/j.lanepe.2023.100638

Repository URI: https://strathprints.strath.ac.uk/85230/